Vaccination policies in most high-income countries attempt to reduce the adverse impact of influenza targeting people aged at least 60 years. However, while it is widely believed that the current immunization strategy saves many lives, influenza infection still remains a severe burden in aged individuals leading to a wide debate on the exact magnitude of the benefit of vaccination in this population. The first aim of the present review is to examine how effective current influenza-vaccine strategies are in aged adults, by analysing which are the most important factors modulating the interpretation of study results in this population. Furthermore, consideration will be given to how immune factors influence the measurement of vaccine efficacy/effectiveness, where advancing age leads to deleterious changes in the adaptive immune system, resulting in less than optimal responses to infectious agents and vaccination. Finally this review concludes with possible strategies to improve the ability of the senescent immune system to respond to vaccination.
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Introduction
Vaccine preventable diseases (VPDs) remain a severe burden in adult populations of developed countries (Michel and Lang, 2011) . In the United States, they account for more than 70,000 deaths per year in these populations compared with 200 deaths in children (Poland et al., 2009) . Aside from a 350-fold increased likelihood of death, VPDs are also associated with an age-related increase in serious adverse health events leading to hospitalization, debilitating complications and/or death (Michel and Lang, 2011) . Deleterious changes in the adaptive immune system mainly associated with advancing age are major contributors to a less than optimal response either to the vaccination or to infectious agents (Aspinall and Goronzy, 2010) .
Foremost amongst VPDs is influenza. Worldwide estimates indicate that influenza infections cause 3-5 million of severe cases per year resulting in 250,000-350,000 deaths (Influenza, 2008) . In the European Union, between 40,000 and 220,000 deaths per year have been attributed to infection by influenza (Seasonal Human Influenza and Vaccination, 2010) . The highest prevalence mainly occurs amongst older adults especially those with chronic medical conditions or immunological disorders, resulting in increased mortality in these high risk groups (World Health Organization, 2005) . However, mortality is just the tip of the iceberg in terms of disease burden, as it can also act as a trigger for functional decline leading to disability in some aged individuals (Monto et al., 2009; McElhaney, 2005; Greenberg and Piedra, 2004; Gavazzi and Krause, 2002) . Such outcomes represent a considerable economic burden amounting to $87 billion each year in the United States (Molinari et al., 2007) . While it is widely believed that influenza vaccination saves many lives, prompting the widespread use of trivalent inactivated influenza vaccine (TIVs -300 million doses produced each year) the exact magnitude of the benefit of the current immunization strategy in the aged population is still controversial (Jefferson, 2006; Fireman et al., 2009; Jackson et al., 2006a Jackson et al., ,b, 2008 Simonsen et al., 2007 Simonsen et al., , 2009 . This review will aim to examine how effective current influenza-vaccine strategies are in aged adults and analyse which are the most important factors modulating the interpretation of study results in this population. Furthermore, consideration will be given to how immune factors influence the measurement of vaccine efficacy/effectiveness. This review will conclude with possible strategies to improve the ability of the senescent immune system to respond to vaccination.
